Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McGill University
$105,000.00
The Role of Inducible Nitric Oxide Synthase (iNOS) in Promoting Cytokine-Induced Cachexia
FY 2018-19
Summary
Historically overlooked, cachexia is a debilitating illness that currently has no available treatments. Cachexia develops in patients suffering from inflammatory diseases such as cancer and is marked by uncontrolled and involuntary muscle and fat loss. The muscle loss within cachectic patients is believed to be the predominant cause of its pathology leading to dramatic decreases in patient quality of life. Cancer patients suffering from cachexia are also significantly less responsive to their treatments and have much higher mortality rates. As a result, this draining disease that almost doubles the durations of hospitalization for patients, not only places a serious financial burden on patients' families, but also on the health care system. Due to its significant impacts on patient wellbeing and its economic burden, there is a strong need to develop treatments for cachexia.
Currently it is believed that cachexia is caused by the elevation of several inflammatory factors that are made during our body's response to overlying diseases. The fundamental mechanisms induced by these factors, which drive the negative symptoms of cachexia are poorly understood. Due to the complex nature of the disease, all previous attempts to treat it have failed; therefore, further investigations into the main drivers of its pathology may uncover more efficacious treatment strategies. An accumulating body of evidence suggests that the enzyme inducible nitric oxide synthase (iNOS) is a primary promoter of cachexia. iNOS has been observed to target and disrupt factors involved in metabolism within muscle cells, and the programs required for muscle formation, integrity, and activity. We believe that revealing the targets of iNOS could unveil potential drug targets to help alleviate this disease.
Department
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
404072
Name
Sadek Jason
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
The Role of Inducible Nitric Oxide Synthase (iNOS) in Promoting Cytokine-Induced Cachexia
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Cachexia; Chronic Inflammation; Human Antigen R (Hur); Inducible Nitric Oxide Synthase (Inos); Mitochondrial Metabolism; Myogenic Factors; Nitrosylation; Post-Transcriptional Regulation; Primary Muscle Cells; Pro-Inflammatory Cytokines
Abstract
Historically overlooked, cachexia is a debilitating illness that currently has no available treatments. Cachexia develops in patients suffering from inflammatory diseases such as cancer and is marked by uncontrolled and involuntary muscle and fat loss. The muscle loss within cachectic patients is believed to be the predominant cause of its pathology leading to dramatic decreases in patient quality of life. Cancer patients suffering from cachexia are also significantly less responsive to their treatments and have much higher mortality rates. As a result, this draining disease that almost doubles the durations of hospitalization for patients, not only places a serious financial burden on patients' families, but also on the health care system. Due to its significant impacts on patient wellbeing and its economic burden, there is a strong need to develop treatments for cachexia.
Currently it is believed that cachexia is caused by the elevation of several inflammatory factors that are made during our body's response to overlying diseases. The fundamental mechanisms induced by these factors, which drive the negative symptoms of cachexia are poorly understood. Due to the complex nature of the disease, all previous attempts to treat it have failed; therefore, further investigations into the main drivers of its pathology may uncover more efficacious treatment strategies. An accumulating body of evidence suggests that the enzyme inducible nitric oxide synthase (iNOS) is a primary promoter of cachexia. iNOS has been observed to target and disrupt factors involved in metabolism within muscle cells, and the programs required for muscle formation, integrity, and activity. We believe that revealing the targets of iNOS could unveil potential drug targets to help alleviate this disease.
Competitiondate
201810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Sadek, Jason
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~